NCT03053219View on ClinicalTrials.gov

Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

December 31, 2018

Conditions
Carcinoma，Non-Small-Cell Lung
Interventions
DRUG

AC0010

Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours

Trial Locations (1)

Unknown

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

Hangzhou ACEA Pharmaceutical Research Co., Ltd.

INDUSTRY

NCT03053219 - Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment | Biotech Hunter | Biotech Hunter